BioCryst Pharmaceuticals down after quarterly revenue miss

BioCryst Pharmaceuticals

03/11/2025 18:24

** Shares of drugmaker BioCryst Pharmaceuticals  BCRX.O down ~ 4% at $7.03

** Posts Q3 revenue of $159.4 million, missing analysts' estimate of $163 million- data compiled by LSEG

** BCRX narrows 2025 revenue forecast for its skin disease drug orladeyo to between $590 million and $600 million from $580 million and $600 million

** Up to last close stock down nearly 3%, YTD

 (Reporting by Koyena Das in Bengaluru)

 ((koyena.das@thomsonreuters.com))